Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex

The University of Texas Health Science Center at Tyler170 enrolled

Overview

Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections who have failed or are intolerant of rifampin. Rifabutin may be a reasonable alternative agent in patients who fail rifampin or or intolerant of rifampin.

Rifabutin dosage 150-300 mg daily( depending upon age, and clinical conditions) in NTM patients who fail treatment with rifampin.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

170

Conditions

Nontuberculous Mycobacterial Infections

Interventions

RifabutinDRUG

Rifabutin dosage dependent on clinical factors such as age, weight, and patient-specific health status

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults age 18 and older with positive acid-fast bacilli smears and cultures for drug-resistant mycobacteria Exclusion Criteria: * Children less than 18 years of age * Pregnancy * Low platelet count, except with very serious disease

Locations (1)

The University of Texas Health Science Center at Tyler

Tyler, Texas, United States

Outcomes

Primary Outcomes

Clinical and microbiological outcomes (e.g. clinical symptoms, laboratory cultures)

neg cultures X3( sputum conversion)

Time frame: 6 mos

Secondary Outcomes

Microbiological Cultures

neg cultures for 1 yr on treatment

Time frame: 1year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.